Annals of Hepatology (May 2013)

The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats

  • Larissa Widholzer Galant,
  • Ângelo Alves de Mattos,
  • Eduardo Menti,
  • Fabiana Borba Valiatti,
  • Ângelo Zambam de Mattos,
  • Marilene Porawski,
  • Antônio Hartmann,
  • Cláudia Ramos Rhoden

Journal volume & issue
Vol. 12, no. 3
pp. 425 – 433

Abstract

Read online

Background/aims. Hepatocellular carcinoma is one of the most commonly diagnosed malignant tumors in the world, and it typically has a poor prognosis. Extensive studies have examined the effects of non-steroidal anti-inflammatory drugs selective to COX–2 on the chemoprevention of various tumors. The objective of this study is to observe the effect of celecoxib on the development of liver tumors in rats.Material and methods. Hepatocellular carcinoma was induced in a group of 75 rats with the carcinogen diethylnitrosamine. The animals were divided into 5 groups. Three groups received various doses of celecoxib, one group received indomethacin, and a control group received no non-steroidal selective anti-inflammatory drugs.Results. The experimental model was considered to be successful because 78% of the rats in the control group developed liver tumors. The number of neoplastic lesions was similar among the celecoxib, indomethacin and control groups, although the nodule diameter of the lesions was smaller in the celecoxib group. Better results were observed in animals that received celecoxib at doses of 6 and 9 mg/kg/ day; 4 rats in these groups did not show any neoplastic histological lesions, and a greater proportion of the nodules in the other animals in these groups were benign than in the groups that did not use celecoxib.Conclusions. These results suggest that celecoxib may play a role in modifying the natural history of hepatocellular carcinoma development.

Keywords